FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. AD-1-1	SERIAL NO. not yet assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Page 1 of 1	APPLICANT Nancy Wisnewski, Kevin S. Brandt	
	FILING DATE October 2, 2003	GROUP

U.S. PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	ISSUE DATE	PATENTEE	CLS	SUB-CLS	FILE DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATIONS

EXAM. INITIAL		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLS	SUB-CLS	TRANS ?

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

YP	C1	Dubois et al., 1998, *The FASEB Journal*, Vol. 12, pp. 1063-1072
YP	C2	Giuliano et al., 1999, *British Journal of Pharmacology*, Vol. 126, pp. 1824-1830
YP	C3	Golden et al., 1999, *Rheumatic Disease Clinics of North America*, Vol. 25, No. 2, pp. 359-378
YP	C4	Khan et al., 1998, *Toxicologic Pathology*, Vol. 26, No. 5, pp. 612-620
YP	C5	Laufer et al., 1999, *Inflamm. res.*, Vol. 48, pp. 133-138
YP	C6	Masferrer et al., 1994, *Proc. Natl. Acad. Sci. USA*, Vol. 91, pp. 3228-3232
YP	C7	Ricketts et al., 1998, *AJVR*, Vol. 59, No. 11, pp. 1441-1446
YP	C8	Riendeau et al., 1997, *Can. J. Physiol. Pharmacol.*, Vol. 75, pp. 1088-1095
YP	C9	Seibert et al., 1994, *Proc. Natl. Acad. Sci. USA*, Vol. 91, pp. 12013-12017
YP	C10	Vane et al., 1998, *Annu. Rev. Pharmacol. Toxicol.*, Vol. 38, pp. 97-120
YP	C11	Vane et al., 1995, *Inflamm Res*, Vol. 44, pp. 1-10
YP	C12	Warner et al., 1999, *Proc. Natl. Acad. Sci. USA*, Vol. 96, pp. 7563-7568

EXAMINER /Yong Pak/ DATE CONSIDERED 07/27/2006

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.